Moderna Sues Pfizer/BioNTech Over Vaccine Patent |
American pharmaceutical company Moderna has sued its rival Pfizer and its German partner BioNTech.
Moderna alleges that its competitors have infringed on patents in the development of a vaccine against COVID-19, using its technology coronavirus copied years before the pandemic.
Information about the claim for monetary compensation USAIt is emphasized that the case was filed in the District Court and that it will also be appealed to the German court.
The CEO of the company says that court 20 of Moderna’s claims10started to develop in , billions dollars aims to protect the innovative technology it invested in and patented long before the COVID-19 pandemic.
In the Moderna lawsuit USA requires royalty payments on commercial sales of the Pfizer/BioNTech vaccine after March 8, 2022, except for sales to its government and low- and middle-income countries.
It is noted that Moderna applied to the court only now, because 2020In October, he promised not to defend his patents during the pandemic to ensure global access to vaccines.
The company is not seeking a ban on the competitor’s vaccine, and it does not intend to extend its patent to low- and middle-income countries.
Pfizer and BioNTech do not accept the rival company’s claims, saying they are confident in their intellectual property and will defend themselves against the charges.
Other pharmaceutical companies previously filed similar lawsuits against Pfizer, BioNTech and Moderna.
Moderna and Pfizer/BioNTech coronavirus vaccines appeared almost simultaneously.
Pfizer/BioNTech vaccine 20 for the first time20in December USAapproved for emergency use in The same approval was given to Moderna a week later.
The introduction of the vaccine in 2022 is already about 22 to Pfizer billion dollarsand Moderna is about half of that – 10,4 billion dollars won.